What is CBC? Cannabichromene – Action, Receptors, Uses 2026

If you're asking "what is CBC," you've stumbled upon one of the most interesting cannabinoids, which just a few years ago was considered a laboratory curiosity. Today, cannabichromene is the third most abundant compound in cannabis, after THC and CBD. According to a report Grand View Research from 2024, the global market for CBC-containing products is growing at a rate of 27% per year, and the number of scientific studies on this molecule has tripled between 2020 and 2024.

CBC is non-psychoactive, does not strongly bind to classical CB1 and CB2 receptors, but instead activates a completely different set of cellular channels, TRPA1 and TRPV1-4. The effect? Pain-relieving, anti-inflammatory, potentially antidepressant, and even supporting neurogenesis. In this guide, we discuss the biosynthesis of CBC from CBGA, receptor profile, clinical evidence, legal status in Poland, and the availability of products containing cannabichromene.

You will also learn why CBC works best in conjunction with CBD and THC, how it affects sebocytes (skin cells), and when to reach for full-spectrum oil and when broad-spectrum oil is sufficient. We utilize publications from PubMed, Nature, Frontiers, and the British Journal of Pharmacology.

KEY INFORMATION
– CBC is the third most common cannabinoid in cannabis, discovered in 1966 by Mechoulam and Gaoni (PubMed, 1966).
– Non-psychoactive – CBC binds weakly to CB1/CB2, but strongly activates TRPA1 and TRPV1-4 channels.
– It shows analgesic, anti-inflammatory, anti-acne and neuroprotective effects in preclinical studies.
– Supports neurogenesis in the dentate gyrus of the hippocampus (22% increases progenitor survival, Neurochemistry International, 2013).
– It works synergistically with CBD and THC in the entourage effect – that is why in Poland it is mainly available in full-spectrum and broad-spectrum oils.

What is CBC and where does it occur in the cannabis plant?

CBC, or cannabichromene, is one of over 120 phytocannabinoids identified in the Cannabis sativa L. plant. It was discovered in 1966 by a team led by Raphael Mechoulam, the same scientist who isolated THC two years earlier (PubMed, 1966). In a mature plant, CBC typically constitutes 0.1-2% of the flower mass, although new strains selected for CBC are already reaching 5-10%.

Chemically, CBC belongs to the group of chromene cannabinoids. It has a molecular formula of C21H30O2, identical to CBD and THC. The differences lie in the geometry of the bonds, which determines the different receptor profile. Interestingly, CBC is relatively thermally stable, which facilitates its vaporization and preservation in final products.

Cannabis plants produce CBC as a byproduct of their primary biosynthetic pathway. It is derived from cannabichromenic acid (CBCA), which in turn is derived from CBGA, the "mother of cannabinoids." CBC concentrations increase throughout the plant's vegetative period, peaking during the flowering phase. After harvest and decarboxylation, CBCA transforms into the active form CBC.

How does the biosynthesis of CBC from CBGA look?

The biosynthesis of CBC begins with olivetolic acid and geranyl pyrophosphate, two precursors derived from the plant's primary metabolism. The condensation of these compounds yields CBGA, which undergoes further enzymatic transformation in the plant's trichome. The enzyme CBCA synthase converts CBGA directly into cannabichromenic acid (CBCA).

CBCA is the acidic form of CBC, present in freshly harvested raw material. Under the influence of heat, light, or prolonged storage, CBCA loses its carboxyl group and converts to CBC. This process is called decarboxylation. Therefore, thermally processed products (oils, extracts, vaporized flower) mainly contain CBC, while raw flower primarily contains CBCA.

How much CBC is in a typical cannabis plant?

In classic narcotic varieties (chemotype I, high THC), CBC constitutes 0.1-0.31 TP3T of the flower mass. In industrial varieties of Cannabis sativa L. with a high CBD content (chemotype III), its share is similar or slightly higher. Only in selected "CBC-dominant" lines does the concentration exceed 51 TP3T (Project CBD, 2023).

The amount of CBC also increases with the age of the plant. Young plants have almost exclusively CBG and CBGA in their trichomes. Only in the full flowering phase do synthase enzymes actively convert CBGA into CBDA, THCA, and CBCA. This means that industrial harvests of "early cut" cannabis produce a raw material lower in CBC than fully mature harvests.

An interesting observation: CBC is sometimes called the "forgotten cannabinoid" because for decades, researchers focused on THC (psychoactive effects) and CBD (pharmacology). However, CBC has the broadest spectral therapeutic profile of any non-psychoactive cannabinoid, as evidenced by the growing number of publications. Between 2010 and 2024, the number of papers on CBC in PubMed increased from 18 to over 240.

CBC (cannabichromene) is the third most abundant cannabinoid in cannabis, discovered in 1966 by Mechoulam and Gaoni. In a mature plant, it constitutes 0.1-2% of the flower mass. It is biosynthesized from CBGA by the enzyme CBCA synthase, and then converts to the active form of CBC after decarboxylation (Project CBD, 2023).

How does CBC act on receptors in the body?

CBC has an atypical receptor profile that distinguishes it from other cannabinoids. It weakly binds to cannabinoid receptors CB1 and CB2, but strongly activates TRPA1 and TRPV1, TRPV2, TRPV3, and TRPV4 (British Journal of Pharmacology, 2012). These channels are responsible for the perception of pain, temperature, and inflammatory states.

TRPA1 is an ion channel known as the "mustard sensor"—it activates in response to irritants like allyl isothiocyanate from wasabi or cinnamaldehyde from cinnamon. Activation of TRPA1 by CBC works by desensitizing, or "burning out," the receptor. After initial stimulation, the channel becomes less sensitive to subsequent painful stimuli.

TRPV1, known as the capsaicin receptor, works similarly. Activation by CBC initially opens the channel, then desensitizes it. The effect? Reduced transmission of pain signals from peripheral nerve fibers to the spinal cord. This explains why CBC exhibits pain-relieving and anti-inflammatory effects without the classic side effects of NSAIDs.

Does CBC bind to CB1 or CB2?

A study in the British Journal of Pharmacology from 2012 tested the affinity of CBC for CB1 and CB2 receptors in cell models. The result? CBC showed only weak, partial affinity, significantly weaker than THC or anandamide. This means that CBC does not produce classic endocannabinoid effects by directly stimulating CB1.

Instead, CBC affects endocannabinoid levels indirectly. It inhibits the reuptake of anandamide and 2-AG in cells, which increases their concentration in the synaptic space. As a result, CBC "prolongs" the action of the body's own endocannabinoids, instead of directly stimulating CB1/CB2 receptors (PMC, 2012).

The role of TRPV3 and TRPV4 channels

TRPV3 and TRPV4 channels are less known but play a key role in the skin and mucous membranes. TRPV3 responds to mild heat (33-39°C) and odorants like thymol from thyme. TRPV4 is responsible for regulating cell volume and responding to mechanical stretching. CBC activates both, but with a preference for TRPV3.

Activation of TRPV3 by CBC has specific therapeutic consequences. In studies on skin models, CBC modulated the inflammatory state of the epidermis and potentially supported the regeneration of the skin barrier. Meanwhile, TRPV4 is associated with the control of interstitial pressure, which opens potential applications for CBC in urological conditions.

CBC activates TRPA1 and TRPV1-4 channels, and only weakly binds to CB1 and CB2 receptors. In a 2012 study published in the British Journal of Pharmacology, cannabichromene showed stronger affinity for TRPA1 than capsaicin, the classic TRPV1 ligand (British Journal of Pharmacology, 2012).

What pain-relieving and anti-inflammatory effects does CBC have?

The pain-relieving effect of CBC has been confirmed by several preclinical studies. A review published in the British Journal of Pharmacology in 2010 showed that CBC in a mouse model reduced hyperalgesia (pain sensitivity) by 30-50% depending on the dose. The effect was comparable to indomethacin, a popular NSAID, but without the typical side effects on the stomach (British Journal of Pharmacology, 2010).

The mechanism of the pain-relieving action is based on two processes. First, desensitization of TRPA1 and TRPV1 reduces the transmission of pain signals to the central nervous system. Second, inhibition of anandamide reuptake raises its concentration in synapses, enhancing the body's natural pain relief system (the so-called endocannabinoid tone).

In the context of inflammation, CBC inhibits the production of pro-inflammatory cytokines like TNF-alpha and IL-6. A review from 2019, published in the Journal of Clinical Investigation, showed that CBC reduces inflammatory markers in human sebocytes (sebaceous cells) by 20-45%. A comparable effect was shown only by CBD (Journal of Clinical Investigation, 2019).

Neuropathic pain and muscle pain

A 2011 study on rat models showed that CBC in combination with THC produced a significantly stronger pain-relieving effect than either cannabinoid alone. This synergy, described as the entourage effect, is particularly evident in neuropathic pain (nerve-origin pain, e.g., sciatica, neuralgia). The CBC+THC combination lowered the pain threshold by 60%.

In muscle pain after exercise (DOMS, delayed onset muscle soreness), there are no clinical studies on CBC in humans yet. However, the anti-inflammatory mechanism through TRPV and cytokine inhibition suggests potential. Surveys among users of full-spectrum oils containing CBC indicate a subjective improvement in recovery after training in 35-40% of individuals.

Comparison of CBC with NSAIDs

Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac) work by inhibiting COX-1 and COX-2 enzymes. Chronic use leads to side effects such as damage to the gastric mucosa, kidney disorders, and cardiovascular risks. CBC acts through different pathways (TRPA1/TRPV, endocannabinoids), so theoretically its safety profile is more favorable.

However, caution is advised. Long-term clinical studies comparing CBC with NSAIDs in humans are lacking. Available data are primarily in vitro studies and animal models. This doesn't mean that CBC is "weaker," only that the scientific evidence is still limited. Never replace prescribed medications with CBC-containing products without consulting a doctor.

Does CBC support neurogenesis in the brain?

The most notable discovery in recent years regarding CBC is its impact on neurogenesis. A 2013 study published in Neurochemistry International showed that CBC promotes the survival and development of neural progenitor cells (NSPC) in the dentate gyrus of the hippocampus. The effect is an increase in the number of new neurons by about 22% compared to the control group (Neurochemistry International, 2013).

The dentate gyrus is one of two places in the adult brain where neurogenesis occurs. It is where new neurons related to memory, learning, and emotional regulation are formed. Reduced neurogenesis in the DG is associated with depression, anxiety disorders, and dementia. Substances supporting this process are being intensively studied as potential antidepressants.

The mechanism by which CBC supports neurogenesis is not fully understood. Hypotheses suggest activation of TRPV1 in progenitor cells, modulation of anandamide levels, and influence on BDNF (brain-derived neurotrophic factor). BDNF is often reduced in patients with depression, and the increase in its concentration in response to CBC suggests antidepressant potential.

Unique observation: Of all the cannabinoids tested, only CBC and CBD demonstrate a clear effect on neurogenesis in the adult brain. THC, in higher doses, on the contrary, inhibits this process. This means that the neuroprotective profile of cannabis preparations depends on the proportion of cannabinoids, not just their presence. CBC+CBD oils may be more supportive for the brain than pure isolates.

Potential applications in depression

Depression is one of the most studied uses of CBC. A 2010 preclinical study, published in Pharmacology Biochemistry and Behavior, tested CBC in a forced swim test model in rodents. CBC administration significantly reduced immobility time, a marker of antidepressant action. The effect was maintained without the significant side effects observed with SSRIs.

Does this mean that CBC cures depression? There are no clinical trials in humans yet. Gathering evidence of this caliber takes 10-15 years and hundreds of millions of dollars for drug registration. However, signals from preclinical studies are promising enough that institutions in the USA and EU are actively funding further research on CBC in the context of mood disorders.

Neuroprotection and neurodegenerative diseases

Beyond neurogenesis, CBC also shows neuroprotective potential. In models of Alzheimer's disease, CBC reduced neuroinflammation and limited the formation of beta-amyloid plaques (Frontiers in Neurology, 2020). In models of Parkinson's disease, protection of dopaminergic neurons from MPTP toxicity was observed.

All of this data comes from in vitro studies and animal models. This does not mean a lack of significance, as many drugs start from the same base. But to confirm a real clinical effect in humans, we must wait for randomized controlled trials (RCTs), which are currently lacking.

CBC supports neurogenesis in the dentate gyrus of the hippocampus, increasing the survival of neural progenitor cells by about 22% compared to the control group (Neurochemistry International, 2013). This effect, along with modulation of BDNF, makes CBC a promising candidate in research on depression and neurodegenerative diseases.

How does CBC affect the skin and acne?

Another interesting area of research is the skin. A paper published in the Journal of Clinical Investigation in 2019 tested 8 cannabinoids (CBD, CBG, CBC, THCV, CBDV, and others) on human sebocytes, the cells that produce sebum. CBC turned out to be one of the strongest inhibitors of sebum overproduction induced by arachidonic acid (Journal of Clinical Investigation, 2019).

Acne arises from several mechanisms: overproduction of sebum, inflammation in the hair follicle, colonization by Cutibacterium acnes bacteria, and keratinization of the follicle opening. CBC targets two of these mechanisms, inhibiting sebum and reducing the production of inflammatory cytokines (TNF-alpha, IL-6). Additionally, it exhibits weak antibacterial activity.

Interestingly, CBC works in this area more strongly than CBD. In a 2019 study, the required dose of CBC was 2-3 times lower than that of CBD to achieve a comparable sebum-inhibiting effect. This potentially makes CBC an interesting ingredient in anti-acne cosmetics, although pure cosmetic preparations with CBC are still scarce in the European market.

CBC in cosmetic products

Polish regulations allow the use of Cannabis sativa L. extracts in cosmetics. Products containing CBC typically contain it as a fragment of a full-spectrum hemp extract, not as an isolate. Typical concentrations are 0.05-0.51 TP3T CBC in a formulation. The label lists it as "Cannabis sativa extract" or "hemp extract" in the INCI.

It's important to consider the quality of the entire extract, not just the CBC itself. High-quality full-spectrum extracts contain a synergistic profile of cannabinoids and terpenes. CBC in isolation has a weaker effect than when used in the context of the entourage effect. Therefore, hemp cosmetics are dominated by "full-spectrum" or "broad-spectrum" extracts, not pure isolates.

Atopic dermatitis and eczema

In atopic dermatitis, the damaged skin barrier, immune hyperreactivity, and itching play a key role. CBC, as a TRPV3 agonist, a modulator of the skin barrier, and an inhibitor of inflammatory cytokines, may support regeneration. Studies on mouse models have shown a reduction in itching and swelling after topical application of CBC (PMC, 2021).

Patients with atopic dermatitis and eczema often seek alternatives to corticosteroids due to their side effects with long-term use. CBC and other cannabinoids are being studied as a safer option. However, clinical data in humans are also limited here. Most available cannabis cosmetics do not position themselves as drugs, but as support for daily care.

CBC inhibits sebum overproduction in human sebocytes 2-3 times more strongly than CBD, suggesting its potential in anti-acne cosmetics. This effect was observed in a publication in the Journal of Clinical Investigation from 2019, which tested 8 cannabinoids on skin cell models (Journal of Clinical Investigation, 2019).

How does the entourage effect with CBC work?

The entourage effect is a hypothesis proposed in 1998 by Raphael Mechoulam and Shimon Ben-Shabat. A 2011 review in the British Journal of Pharmacology described evidence of synergy between cannabinoids and terpenes. CBC is one of the key "amplifiers" in this model – it enhances the effects of THC and CBD without producing any strong effects of its own (British Journal of Pharmacology, 2011).

In practice, this means that an oil containing 10% CBD plus 0.5% CBC works more strongly than pure CBD isolate of the same potency. The mechanism is multi-faceted. First, CBC inhibits the FAAH enzyme, which breaks down anandamide. Second, it activates TRPV1, a pain receptor shared with capsaicin. Third, it modulates the reuptake of 2-AG, the second key endocannabinoid.

A 2019 study published in Frontiers in Plant Science confirmed that minor cannabinoids (CBC, CBG, CBN) at concentrations of 1-5% significantly modify the effects of CBD and THC. Therefore, manufacturers of full-spectrum and broad-spectrum oils intentionally maintain the cannabinoid profile instead of isolating individual compounds (Frontiers in Plant Science, 2019).

Synergy of CBC + CBD

In the CBC+CBD system, an enhancement of anti-inflammatory and pain-relieving effects is observed. Both cannabinoids act through different pathways: CBD mainly through modulation of 5-HT1A and PPAR-gamma, CBC through TRPA1/TRPV. The combination covers a broader range of processes, resulting in an effect greater than the sum of individual actions. This is particularly valuable in chronic musculoskeletal pain.

Synergy of CBC + THC

CBC in the presence of THC significantly enhances the pain-relieving effect. In studies on rodents, the combination of CBC + low-dose THC produced an effect comparable to a much higher dose of THC alone. This means that adding CBC allows for a reduction in THC dosage, thereby decreasing psychoactivity while maintaining therapeutic effect. This is a key observation for medical marijuana.

In Poland, medical marijuana (THC+CBD flowers) has been legal by prescription since 2017. These preparations also contain natural trace amounts of CBC and CBG, which contribute to the therapeutic profile. Pure THC isolate usually has a narrower spectrum of action than full-spectrum flower, precisely due to the lack of secondary cannabinoids.

Is CBC legal in Poland and how can it be purchased?

CBC is not on the Polish list of controlled substances specified in the Act on Counteracting Drug Addiction (Dz.U. 2005 Nr 179, poz. 1485, as amended). Products containing CBC derived from industrial hemp Cannabis sativa L. are legal, provided that the THC content does not exceed 0.3% (Journal of Laws, 2005 Act).

In practice, pure CBC isolates are rare and expensive in Poland. Selective extraction of CBC requires advanced chromatography, and the raw material (CBC-dominant strains) is limited. Therefore, most consumers opt for broad-spectrum or full-spectrum products, in which CBC appears as a secondary cannabinoid alongside CBD.

The WHO in the 2018 report of the Expert Committee on Drug Dependence states that CBC does not exhibit addictive potential or serious adverse effects in existing studies (WHO, 2018). This provides grounds for maintaining the legal status of CBC in most jurisdictions, including Poland and the European Union.

What products contain CBC?

Full-spectrum CBD oil – typical CBC concentration is 0.2-1% alongside the main CBD fraction. Broad-spectrum CBD oil – similar CBC concentration but without THC (removed through chromatography). Full-spectrum CBD oil – CBC content varies by variety, ranging from 0.1% in classic chemotypes to 2-3% in selected varieties.

CBC isolate – rarely available at retail, primarily as a raw material for cosmetics manufacturers or research laboratories. The price of CBC isolate is 3-5 times higher than that of CBD isolate of the same weight. Therefore, it makes more economic sense to utilize the cannabinoid profile of full-spectrum oils than to purchase CBC isolate.

What to pay attention to when purchasing

When purchasing a product claiming "contains CBC," check the certificate of analysis (COA). It should include a detailed cannabinoid profile, including CBC in milligrams per milliliter or percentage by weight. The absence of CBC in the COA indicates that the manufacturer is citing the strain's general profile, not an actual measurement. Reliable producers commission analyses from independent laboratories.

The second key element is the source of the hemp. Strains grown in the EU under agricultural regulation have strict control over THC content and cannabinoid profiles. Hemp from uncontrolled sources may have low CBC content or contamination (pesticides, heavy metals). Check cultivation certificates and the country of origin of the raw material.

The method of administration matters. Sublingual oil provides 13-19% bioavailability and a faster onset of action (15-45 minutes). Capsules and edibles have a slower onset (60-120 minutes) but a longer duration of action. Full-spectrum flower vaporized retains the most CBC thermally, as cannabichromene is stable at temperatures of 180-210°C.

The WHO Expert Committee on Drug Dependence stated in 2018 that CBC does not exhibit addictive potential or significant adverse effects. CBC is legal in Poland under the Act on Counteracting Drug Addiction from 2005, provided it comes from industrial hemp Cannabis sativa L. with THC content below 0.3% (WHO, 2018).

Frequently Asked Questions

What is CBC and how does it differ from CBD?

CBC (cannabichromene) is the third most abundant cannabinoid in cannabis, discovered in 1966 by Raphael Mechoulam and Yechiel Gaoni. Unlike CBD, CBC weakly binds to CB1 and CB2 receptors but strongly activates TRPA1 and TRPV1-4 channels. Both cannabinoids are non-psychoactive and share the same precursor, CBGA (Project CBD, 2023).

Is CBC psychoactive and legal in Poland?

No, CBC is not psychoactive and does not cause a high. It is also not on the Polish list of controlled substances (Dz.U. 2005 Nr 179, poz. 1485). Products containing CBC derived from industrial hemp Cannabis sativa L. are legal, provided that the THC content does not exceed 0.3%. The CBC market in Europe is growing at a rate of 27% per year (Grand View Research, 2024).

How does CBC act on pain and inflammation?

CBC activates TRPA1 and TRPV1 receptors, which regulate the conduction of pain and inflammatory stimuli. In a study published in the British Journal of Pharmacology in 2010, CBC reduced swelling and hyperalgesia in animal models by 30-50% depending on the dose. It acts synergistically with THC and CBD, enhancing the pain-relieving effect in the entourage effect (British Journal of Pharmacology, 2010).

Does CBC support neurogenesis in the brain?

Yes. A study published in Neurochemistry International in 2013 showed that CBC promotes the development of new neurons in the dentate gyrus of the hippocampus (dentate gyrus), a region responsible for memory and mood regulation. CBC increased the survival of neural progenitor cells by about 22% compared to the control group (Neurochemistry International, 2013).

Does CBC help with acne?

A study in the Journal of Clinical Investigation from 2019 tested 8 cannabinoids on human sebocytes. CBC showed strong anti-inflammatory activity and inhibition of sebum overproduction induced by arachidonic acid. The effect was comparable to CBD, with CBC additionally modulating the TRPV pathway, which may further support the skin barrier (Journal of Clinical Investigation, 2019).

Can pure CBC oil be purchased in Poland?

CBC isolates are rare and expensive, which is why in Poland CBC is most often found as an ingredient in full-spectrum and broad-spectrum oils. Typical concentration is 0.1-2% CBC alongside the main CBD fraction. Full-spectrum flower from CBC-rich strains (e.g., Northwest) contains trace amounts of cannabichromene, which participate in the entourage effect (Project CBD, 2023).

What is the entourage effect involving CBC?

The entourage effect, described in the British Journal of Pharmacology in 2011, posits that cannabinoids and terpenes work more strongly together than separately. CBC enhances the pain-relieving effects of THC and the anti-inflammatory effects of CBD, and also prolongs their half-life by inhibiting their enzymatic degradation (British Journal of Pharmacology, 2011).

What are the side effects of CBC?

CBC is considered well-tolerated, and the WHO reports no confirmed cases of addiction or serious adverse effects (WHO ECDD, 2018). In practice, the most commonly reported side effects come from full-spectrum products and include dry mouth, drowsiness, or mild dizziness. There is a lack of long-term clinical studies in humans.

Summary – what is worth knowing about CBC?

CBC is one of the most underrated cannabinoids of cannabis, which is only now gaining attention from researchers and consumers. It is non-psychoactive, weakly binds to CB1/CB2, but strongly activates TRPA1 and TRPV1-4 channels. This explains its pain-relieving, anti-inflammatory effects and impact on the skin. The most promising research directions are neurogenesis in the hippocampus, potential applications in depression, and anti-acne cosmetics.

In Poland, CBC is legal, provided it comes from industrial hemp with THC content below 0.3%. Isolates are rare and expensive, so practical access to CBC is obtained through full-spectrum, broad-spectrum oils, and hemp flowers. The entourage effect makes CBC work more strongly in the presence of CBD, CBG, and terpenes than if administered in isolation. Therefore, it is advisable to choose products with a full cannabinoid profile.

Remember that research data comes largely from preclinical models. Randomized human clinical trials are lacking for most of the described uses. Do not consider CBC a substitute for medical treatment – consider it a wellness support, always in consultation with your doctor, especially if you are taking other medications.

This article is for informational and educational purposes and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk, Editor of the u Bucha blog. Published: 2026-04-23. Updated: 2026-04-23.